Canada - English - Health Canada

bausch health, canada inc. - azilsartan medoxomil (azilsartan medoxomil potassium) - tablet - 80mg - azilsartan medoxomil (azilsartan medoxomil potassium) 80mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

merck canada inc - raltegravir (raltegravir potassium) - tablet (chewable) - 25mg - raltegravir (raltegravir potassium) 25mg - hiv integrase inhibitors

Canada - English - Health Canada

merck canada inc - raltegravir (raltegravir potassium) - tablet (chewable) - 100mg - raltegravir (raltegravir potassium) 100mg - hiv integrase inhibitors

Canada - English - Health Canada

bausch health, canada inc. - azilsartan medoxomil (azilsartan medoxomil potassium); chlorthalidone - tablet - 40mg; 12.5mg - azilsartan medoxomil (azilsartan medoxomil potassium) 40mg; chlorthalidone 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

bausch health, canada inc. - azilsartan medoxomil (azilsartan medoxomil potassium); chlorthalidone - tablet - 40mg; 25mg - azilsartan medoxomil (azilsartan medoxomil potassium) 40mg; chlorthalidone 25mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

merck canada inc - raltegravir (raltegravir potassium) - tablet - 600mg - raltegravir (raltegravir potassium) 600mg - hiv integrase inhibitors

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - azilsartan kamedoxomil (unii: wec6i2k1fc) (azilsartan - unii:f9nux55p23) - azilsartan medoxomil 40 mg

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - raltegravir potassium (unii: 43y000u234) (raltegravir - unii:22vkv8053u) - raltegravir 400 mg - isentress1 is indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adult patients. this indication is based on analyses of plasma hiv-1 rna levels up through 48 weeks in three double-blind controlled studies of isentress. two of these studies were conducted in clinically advanced, 3-class antiretroviral (nnrti, nrti, pi) treatment-experienced adults and one was conducted in treatment-naïve adults. the use of other active agents with isentress is associated with a greater likelihood of treatment response [see clinical studies (14)] . the safety and efficacy of isentress have not been established in pediatric patients. registered trademark of merck & co., inc. copyright © 2007, 2009 merck & co., inc. all rights reserved none pregnancy category c isentress should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there are no adequate and well-controlled studies in pregnant women. in addi

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - raltegravir potassium (unii: 43y000u234) (raltegravir - unii:22vkv8053u) - raltegravir 400 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - raltegravir potassium (unii: 43y000u234) (raltegravir - unii:22vkv8053u) - raltegravir 400 mg